• Citations Per Year
Learn More
The potential liability of RS-8359 for the 'cheese' effect that is characteristic of the classical monoamine oxidase inhibitors has been compared with placebo and moclobemide in the tyramine test. Both RS-8359 and moclobemide reduce the dose of tyramine required to raise systolic blood pressure by 30 mmHg by about half, but the risk of the tyramine(More)
RS-8359 is a new reversible inhibitor of monoamine oxidase A (RIMA). With a selectivity ratio of about 2200 for the A:B enzyme types, it is one of the most specific of this class of compounds. As a result, it shows relatively little effect upon blood pressure when administered together with tyramine, thus effectively eliminating the 'cheese' effect which(More)
Electro-oculogram (including saccadic eye movements), auditory-evoked potentials and visual analogue scales for a subjective impression of effects were used to evaluate some pharmacodynamic properties of RS-8359. In the electro-oculogram, administration of central nervous system-stimulating drugs is expected to decrease latency and fixation time and to(More)
RS-8359 is very rapidly absorbed, metabolized and distributed following oral dosing, with significant concentrations of both parent drug and its principal metabolite appearing in plasma within 15 min. Plasma levels were linearly related to doses of up to 300 mg, beyond which absorption was diminished, perhaps due to a saturation effect. Clearance of RS-8359(More)
The safety, tolerability and a preliminary assessment of the efficacy of the new reversible inhibitor of monoamine oxidase A, RS-8359, were evaluated in two studies in hospitalized, depressed patients. Daily doses of 100 and 200 mg divided into two equal doses were compared with moclobemide at 300 mg/day divided into two equal doses. The results indicated(More)
  • 1